Democratic Republic of the Congo & Serum Institute of India

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an outbreak of Ebola Bundibugyo, with 282 confirmed cases and 42 deaths, making it the primary location for vaccine development and trials.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Democratic Republic of the Congo: The epicenter of the outbreak, facing a public health crisis with over 2,100 deaths and strained healthcare infrastructure. The government is coordinating the response but faces challenges from conflict and unpaid health workers.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

Democratic Republic of the Congo: The DRC is the primary focus, facing a severe Ebola outbreak that threatens public health and economic stability; the pope's call may attract aid.

Serum Institute of India: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.

Democratic Republic of the Congo: The Democratic Republic of the Congo is the primary location of the Ebola outbreak, with its eastern provinces being heavily affected. The ongoing conflict within the country hinders efforts to contain the disease, leading to a higher death toll and complicating response activities.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an ongoing outbreak of the Bundibugyo strain of Ebola, leading to the World Health Organization's recommendations for experimental treatments and vaccines.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.